Market Trends of Global Cancer Supportive Care Drugs Industry
This section covers the major market trends shaping the Cancer Supportive Care Drugs Market according to our research experts:
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Segment is Expected to Register High Growth Over the Forecast Period
Various research studies have been published on the insights about the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in cancer treatments. For instance, in February 2021, a research study published titled "Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention" stated that there is growing evidence from epidemiologic, preclinical, and clinical studies suggesting that non-steroidal anti-inflammatory drugs (NSAIDs) play a beneficial role in colorectal cancer chemoprevention. They reduce the risk of colorectal polyps, mostly by cyclooxygenase-2 inhibition. Further, according to a research study published in November 2021, titled 'Nonsteroidal Anti-Inflammatory Drugs Reduce Second Cancer Risk in Patients with Breast Cancer: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan', the use of COX-2 together with non-COX-2 medications during the follow-up could reduce second cancer risk, taking more than one NSAID had varying benefits on reducing the incidence of second cancer. Hence, such research studies increase awareness about the drugs and will increase the market growth.
The launch of new drugs by the market players in the regions is also boosting the growth of the market. For instance, in September 2021, Intas Pharmaceuticals launched Oral Azacitidine in India under the brand name Azadine-O for Acute Myeloid Leukemia. It is approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia. Such launches enhance the accessibility of the drugs and thus boosts the growth of the market segment. Additionally, in July 2020, National Pharmaceutical Regulatory Authority, Malaysia approved a new breast cancer drug named NERLYNX (neratinib). It has shown its significance in reducing the risk of cancer recurrence. The drug is an oral medication taken by women with breast cancer who have had surgery, chemotherapy, and prior trastuzumab-based therapy. Thus, owing to the abovementioned factors, the segment of the studied market is expected to project growth over the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to hold a major market share in the global brucellosis vaccines market. Factors such as the increasing prevalence of diseases and increasing initiatives by the public and private players are anticipated to drive the studied market growth in the country. Although high prevalence leads to a burden on the population of the country, US and Canada have developed healthcare systems and hence spend a lot on the treatment and research in the oncology field. Hence, these countries attract a lot of market players. The increasing research and development funding over the years is also boosting the growth of the market. In April 2022, a study published in Proceedings of the National Academies of Sciences conducted by researchers from NYU Grossman School of Medicine revolves around the dense protein meshwork that supports organs and helps to rebuild damaged tissue. Collagen protein fibers, the major component of the mesh, are continually broken down and replaced to maintain tensile strength, and as part of the wound healing process. The study found that the degraded collagen increased the amount of arginine, an amino acid that is used by the enzyme nitric oxide synthase (iNOS) to produce compounds called reactive nitrogen species (RNS). This, in turn, caused neighboring, supportive stellate cells to build collagen-based meshes around tumors. Such studies would provide new innovative methods for the use of supportive drugs in the treatment of cancer which will increase the market growth.
Furthermore, in January 2020, the Global Cancer Program hosted the "UCSF-Mexico Cancer Collaboration Annual Meeting" with partners, such as Instituto Nacional Cancerologia (INCan), Instituto Nacional de Salud Pública (INSP), and the Instituto Nacional de Medicina Genómica (INMEGEN). The UCSF-Mexico Cancer Initiative aims to strengthen regional cancer research capacity and expand the institutional cancer research portfolios and training activities of partners in Mexico. Thus, the high prevalence and growing research funding for cancer research is expected to drive the growth of the cancer vaccines market in Mexico. Hence, increasing research would increase the market growth in the upcoming period by providing a favorable environment for supportive drug development. Therefore, the prevalence of diseases and increasing initiatives by the public and private players are anticipated to drive the studied market growth in the country.
